Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
421-440 of 604 trials

Breast Cancer Treatment: I-BCT-1 Study

We are exploring how genetic changes in breast tumors can help select the best treatment options for patients. This study includes patients with neoadjuvant and metastatic breast cancer to improve therapy outcomes.

Breast Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Exercise and Statin Use in Advanced Cancer Treatment

We are studying whether supervised exercise and atorvastatin can improve cancer treatment outcomes for patients with advanced breast, renal, ovarian, and prostate cancers. We also want to understand how these interventions affect patients' quality of life and experiences during treatment.

Metastatic Breast, Ovarian, Prostate, and Kidney Cancer≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGynecology and ObstetricsOncologyUrology

Eosinophilic Asthma: Benralizumab Treatment Study

We are studying how well benralizumab works and its safety for people with eosinophilic asthma who are not well-controlled on standard treatments. This trial compares it to increasing their current medication dose.

Eosinophilic Asthma1-2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteAllergologyPulmonology

Ovarian Cancer: ZN-c3 and Niraparib Study

We are studying the safety and effectiveness of a new drug, ZN-c3, alone and with niraparib for patients with platinum-resistant ovarian cancer. This trial aims to find better treatment options for those who have limited choices.

Recurrent Ovarian Cancer>2 yearsSafety phase (I)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Cemiplimab for High-Risk Skin Cancer

We are studying whether the immunotherapy Cemiplimab can help prevent cancer recurrence in patients with high-risk stage III/IV skin cancer who can undergo surgery.

Cutaneous Squamous Cell CarcinomaSurgically Resectable, High Risk Stage III/IV Cutaneous Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDermatologyOncology

Desmoid Tumors: Nirogacestat Study for Women

We are studying how Nirogacestat affects ovarian function in adult premenopausal women with desmoid tumors. The trial aims to understand any ovarian toxicity and the overall safety of the treatment.

Desmoid Tumors (Aggressive Fibromatosis)1-2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Grass Allergy: Vitamin D Enhanced Immunotherapy

We are studying whether combining intralymphatic immunotherapy with vitamin D helps improve allergy symptoms in people with moderate to severe grass allergies during pollen season.

Allergic Rhinitis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesAllergology

MELAS: Testing Zagociguat

We are studying the investigational drug zagociguat to see if it helps reduce fatigue and improve thinking skills in people with MELAS. The trial also looks at its safety and effects on muscle weakness and memory.

MELAS Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Chronic Myeloid Leukemia: Second Stop of TKI Treatment

We are studying whether patients with CML can maintain remission after stopping their medication for a second time. This trial aims to identify factors that may help in achieving better treatment outcomes.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Rett Syndrome: Testing Mirtazapine

We are studying whether Mirtazapine can improve social behavior, anxiety, and sleep quality in patients with Rett syndrome. This research may help us understand how to better manage symptoms of this condition.

Rett Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPsychiatry

IVF Success: Exercise and Mediterranean Diet vs. Aspirin

We are studying whether exercise and a Mediterranean diet can improve live birth rates compared to aspirin for women undergoing in vitro fertilization. This research aims to find better ways to support fertility.

Women's Infertility>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyGynecology and Obstetrics

Chronic Spontaneous Urticaria and Hidradenitis Suppurativa: INF904 Study

We are evaluating the safety of an oral medication called INF904 for people with moderate to severe chronic spontaneous urticaria or hidradenitis suppurativa. This study will help us understand how the medication works in the body.

Chronic Spontaneous UrticariaHidradenitis Suppurativa≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Heart Failure: Sacubitril/Valsartan Treatment

We are studying whether the medication Sacubitril/Valsartan can improve heart function in patients with transthyretin cardiac amyloidosis and heart failure. This trial will help us understand its effects on heart pumping ability.

Transthyretin Cardiac Amyloidosis>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Heart Failure: Engineered Heart Tissue Treatment

We are studying a new type of heart tissue made from stem cells for patients with severe heart failure. The goal is to see if it is safe and effective in improving heart function and related symptoms.

Acute Heart Failure>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Niemann-Pick Type C and GM1/GM2 Gangliosidosis: Nizubaglustat Study

We are investigating how well nizubaglustat works and its safety for children with Niemann-Pick type C disease and GM1 or GM2 gangliosidosis. This study aims to see if it can improve movement and coordination compared to a placebo.

Niemann-Pick Type C Disease and GM1/GM2 Gangliosidoses1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesNeurologyPediatrics

Triple-Negative Breast Cancer: Optimizing Pembrolizumab Use

We are studying whether observing patients after surgery is as effective as continuing pembrolizumab treatment for those who responded well to initial therapy. This trial also looks at safety, quality of life, and fertility impacts.

Early Triple-Negative Breast Cancer (TNBC)6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

HIV Treatment: Comparing DOR/3TC and DTG/3TC

We are studying whether a new two-drug regimen can maintain viral suppression in people living with HIV who are currently stable on a three-drug treatment. This trial will also assess various health outcomes and side effects over time.

HIV Disease>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInfectious Diseases

Atenativ for Congenital Antithrombin Deficiency During Surgery

We are studying how Atenativ may help patients with congenital antithrombin deficiency during surgical procedures or childbirth. The trial looks at its safety, effectiveness, and how the body processes the medication.

Congenital Antithrombin Deficiency>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesGynecology and ObstetricsHematologyInternal Medicine

Advanced Solid Tumors: 89Zr-Df-crefmirlimab Imaging Study

We are studying a new imaging method to see how well it shows cancer cells in patients with advanced solid tumors. This may help us understand treatment responses and immune cell activity better.

Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Myelofibrosis: Study of Pacritinib vs. Standard Treatment

We are investigating whether pacritinib can better reduce spleen size and improve symptoms in patients with myelofibrosis. This trial is for those with severe low platelet counts and compares pacritinib to physician's choice of therapy.

Post-Polycythaemia Vera MyelofibrosisPrimary MyelofibrosisPost-Essential Thrombocythaemia Myelofibrosis3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology